Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone that has the potential to treat retinal diseases The Phase 2 (DX-211) study provides a clinical proof-of-concept of OCS-01 topical drug effect on DME The study met its pre-defined …